As a medical advisor, Olexander Hnojewyj, Ph.D. will add deep experience to the team, in the development of medical devices used in the treatment of vascular disease. Over the past seven years, he has conducted extensive research related to vascular closure sealants and has secured multiple patents and patent applications related to vascular closure.
As Bio-Statistician,
"As we build our operational capabilities, the newest additions to our
team of advisors are vital to our future success," said
About CPC
CPC of America develops therapeutic devices for use in endovascular procedures. CPC's current focus is the completion of development and testing of the MedClose(TM) vascular closure system, an internal puncture-closing system for use in catheter laboratories.
Forward Looking Statements
The statements contained in this press release that are not historical are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
including statements, without limitation, regarding the Company's
expectations, beliefs, intentions or strategies regarding the future. Such
forward-looking statements relate to, among other things: (1) the Company's
continuing development of its MedClose(TM) vascular closure system, (2) the
Company's expectations concerning regulatory approvals of the MedClose system
and the commencement of revenue producing operations based on the sale or
licensing of the MedClose, (3) the business relationship between the Company
and new parties and the expected benefits to the Company from such
relationship, and (4) the commencement of manufacturing of the MedClose
system. These statements are qualified by important factors that could cause
the Company's actual results to differ materially from those reflected by the
forward-looking statements. Such factors include but are not limited to: (1)
the Company's ability to finance the continued development and commencement of
manufacturing of the MedClose system, (2) regulatory approvals of the
MedClose system, (3) the general risks and uncertainties inherent in any new
business relationship such as the one recently entered into between the
Company and its new consultants, and (4) those other risks and factors
described from time to time in the Company's reports filed with the Securities
and Exchange Commission, including but not limited to the Company's Annual
Report on Form 10-K for the year ended
SOURCE CPC of America, Inc.